Roche latest to look to emerging markets as it invests $300m in China
This article was originally published in Clinica
Roche Diagnostics is planning to invest CHF300m ($311m) in China and open nine new offices there in order to expand its presence in the country, according to media reports. The firm hopes to make China its second-largest market – it is currently its fifth-biggest, China Daily reported. The company confirmed the investment to Clinica, but declined to give further details.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.